Cain McClary

Dr. Andrew Cain McClary is the Founder and serves as Managing Partner at KdT Ventures. He serves as Board Member at Azitra and Checkerspot.. He serves as Advisor at 8VC. During his undergraduate studies, he studied proteins involved in the development of appendages, both in the labs of Dr. Kristi Wharton at Brown University and Dr. Fred Kaplan at the University of Pennsylvania. Following Brown, he went on to receive his medical degree from Tulane University School of Medicine in 2012. During medical school, he also spent a year at the National Institutes of Health (NIH) as part of the prestigious Howard Hughes Medical Institute "Cloister" Fellowship, where he studied the role of non-coding RNA in cancer at the National Cancer Institute (NCI) in the lab of Dr. Curtis Harris. Immediately following medical school, he underwent residency training in anatomic pathology at Stanford University, where during his final year, he was named Chief Resident. While in residency, he discovered a genetic mutation in a rare jaw tumor, ameloblastoma. This discovery subsequently led to a successful phase IV clinical trial of BRAF inhibitors in ameloblastoma, a condition where previously surgery was the only option. Due to this success, he was appointed as Assistant Professor in the Department of Pathology at Stanford University, becoming the youngest person on faculty in pathology at the time. He has won several notable awards, spoken at universities and national conferences, and published more than 10 peer-reviewed articles. He serves as Board Member at Debut. He is an Angel Investor. He received his BSc in Biochemistry and Molecular Biology from Brown University in 2007